European CHMP recommends approval of setmelanotide (Imcivree) for treatment of obesity
The full indication is for treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including PCSK1, deficiency or biallelic leptin receptor deficiency in people aged > 6 years.
Source:
European Medicines Agency